GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials

Surrogate end points are needed to assess whether treatments are effective in the early stages of CKD. GFR decline leads to kidney failure, but regulators have not approved using differences in the change in GFR from the beginning to the end of a randomized, controlled trial as an end point in CKD b...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of the American Society of Nephrology Vol. 30; no. 9; p. 1735
Main Authors:	Inker, Lesley A, Heerspink, Hiddo J L, Tighiouart, Hocine, Levey, Andrew S, Coresh, Josef, Gansevoort, Ron T, Simon, Andrew L, Ying, Jian, Beck, Gerald J, Wanner, Christoph, Floege, Jürgen, Li, Philip Kam-Tao, Perkovic, Vlado, Vonesh, Edward F, Greene, Tom
Format:	Journal Article
Language:	English
Published:	United States 01.09.2019
Subjects:	Bayes Theorem Biomarkers Creatinine - blood Disease Progression Glomerular Filtration Rate Humans Kidney Failure, Chronic - etiology Kidney Failure, Chronic - physiopathology Predictive Value of Tests Randomized Controlled Trials as Topic Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - physiopathology Renal Insufficiency, Chronic - therapy meta-analysis GFR chronic kidney disease end stage kidney disease randomized controlled trials
ISSN:	1533-3450, 1533-3450
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!